论文部分内容阅读
背景与目的:我国是肝癌高发地区。上海市最新监测数据显示,肝癌发病率居恶性肿瘤发病前列,疾病负担仍很大。该研究旨在分析上海地区肝癌患者生存率情况,为肝癌的防治提供基础数据。方法:根据上海市肿瘤登记处收集的2002—2006年肝癌登记和生存随访报告资料,采用寿命表法和EdererⅡ法对肝癌患者的观察生存率(observed survival,OS)和相对生存率(relative survival,RS)及其相关人口学和疾病状况特征资料进行分析。结果:纳入分析的上海市2002—2006年诊断的肝癌病例20 702例,1~5年OS分别为32.03%、21.63%、16.51%、13.66%和11.72%,1~5年RS分别为34.21%、23.93%、19.18%、16.84%和15.45%。男性OS较女性OS高,0~34岁年龄段患者OS高于其他年龄组,肝细胞癌的OS高于其他类型,Ⅰ期患者的OS明显高于Ⅲ期和Ⅳ期,市区和郊区居住肝癌患者生存情况差异无统计学意义(P<0.05)。过去30多年来,上海市肝癌患者5年OS和RS改善明显。结论:上海市肝癌患者的生存水平上升明显,但与其他常见恶性肿瘤相比,生存率仍较低,因此,进一步加强危险因素和高危人群的控制和干预是今后肝癌防治工作的重点。
Background and purpose: China is a high incidence of liver cancer. Shanghai’s latest monitoring data show that the incidence of HCC ranks the forefront of malignant tumors, the disease burden is still large. This study aimed to analyze the survival rate of patients with liver cancer in Shanghai and provide the basic data for the prevention and treatment of liver cancer. Methods: According to the data of report of liver cancer registration and survival from 2002 to 2006 collected by Shanghai Tumor Registry, the observed survival (OS) and relative survival (survival) were calculated by the life table method and Ederer Ⅱ method, RS) and its demographic and disease status characteristics were analyzed. Results: A total of 20 702 cases of liver cancer diagnosed in Shanghai from 2002 to 2006 were included in this study. The 1- 5 years OS was 32.03%, 21.63%, 16.51%, 13.66% and 11.72%, respectively. The 1- 5 years RS were 34.21% , 23.93%, 19.18%, 16.84% and 15.45% respectively. The OS of males was higher than that of females. The OS of 0 ~ 34 age group was higher than that of other age groups. The OS of hepatocellular carcinoma was higher than other types. The OS of stage Ⅰ patients was significantly higher than that of stage Ⅲ and Ⅳ. The survival of patients with liver cancer was no significant difference (P <0.05). Over the past 30 years, Shanghai 5-year patients with liver cancer and RS improved significantly. Conclusion: The survival rate of patients with liver cancer in Shanghai increased significantly, but the survival rate was still lower than that of other common malignant tumors. Therefore, further strengthening the control and intervention of risk factors and high-risk groups is the focus of future prevention and treatment of liver cancer.